Is Inhibikase Therapeutics, Inc. (IKT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 42.8% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 42.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.1% / 33% | 98.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 42.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.1% / 33% | 98.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -36.0% | |
| Return on Assets (ROA) | -20.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$19M |
| Free Cash Flow | -$19M |
| Total Debt | $110,517 |
| Current Ratio | 21.7 |
| Total Assets | $99M |
Price & Trading
| Last Close | $1.63 |
| 50-Day MA | $1.77 |
| 200-Day MA | $1.70 |
| Avg Volume | 1.8M |
| Beta | 0.8 |
|
52-Week Range
$1.33
| |
About Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Inhibikase Therapeutics, Inc. (IKT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Inhibikase Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Inhibikase Therapeutics, Inc.'s debt ratio?
Inhibikase Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.1%.
What are Inhibikase Therapeutics, Inc.'s key financial metrics?
Inhibikase Therapeutics, Inc. has a market capitalization of $222M. Return on equity stands at -36.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.